Dealing with Antibiotic Resistance: Antisense Technology

应对抗生素耐药性:反义技术

基本信息

项目摘要

DESCRIPTION (provided by applicant): This proposal targets a critical issue in the fight against the growing problem of antibiotic resistance: the search for strategies aimed at preserving the effectiveness of currently available antibiotics. Our model system is the aminoglycoside 6'-N-acetyltransferase type lb [AAC(6')-lb], an enzyme that mediates resistance to amikacin and other aminoglycosides. Our long term goal is to develop antisense oligonucleotides as pharmacological tools to selectively inhibit the expression of aac(6')-lb. To develop two kinds of antisense compounds that inhibit expression of aac(6')-lb by different mechanisms we designed specific aims 1 and 2: 1. Identification of nuclease-resistant oligodeoxynucleotide analogs that promote RNase H-mediated degradation of aac(6')-lb mRNA. We will design nuclease-resistant analogs and test their ability to mediate phenotypic conversion to amikacin susceptibility and determine the mechanism of action. 2. In vivo studies on RNase P-mediated degradation of aac(6')-lb mRNA by oligoribonucleotides and systematic analysis of the ability of nuclease-resistant oligoribonucleotide analogs to induce RNase P cleavage. We will design plasmids that code for selected oligoribonucleotides and test if they induce RNase P-mediated conversion to amikacin susceptibility. We will also carry out a systematic study on nuclease-resistant oligoribonucleotide analogs to determine which ones, if any, do not compromise RNase P-mediated cleavage of RNA. While achieving specific aims 1 and 2 will be an important step towards developing antisense compounds to preserve the efficacy of amikacin, many problems will remain to be solved. Two of these problems are: a) delivery methods to insure that antisense compounds reach the bacterial cell's cytoplasm are very limited; and b) the aac(6')-lb gene is often found in high copy number plasmids; as a consequence the large number of gene copies may make it very difficult to completely turn off expression. Specific aims 3 and 4 have been designed to deal with these problems: 3. Development of liposome formulations capable of delivering oligonucleotides into the cell's cytosol. We will test the ability of several formulations of cationic liposome-encapsulated oligonucleotide analogs to reach the cytoplasm. The process of internalization will be characterized by fluorescence microscopy. 4. Search for peptide inhibitors of the AAC(6')-lb enzyme. Enzyme inhibitors could have a synergistic activity with antisense oligonucleotides by inhibiting the action of any residual AAC(6')-lb protein synthesized. Peptide inhibitors will be searched using phage display.
描述(由申请人提供):该提案针对的是对抗日益严重的抗生素耐药性问题的一个关键问题:寻找旨在保持现有抗生素有效性的策略。我们的模型系统是氨基糖苷6'-N-乙酰转移酶1b型[AAC(6')-lb],一种介导对阿米卡星和其他氨基糖苷类耐药性的酶。我们的长期目标是开发反义寡核苷酸作为药理学工具来选择性抑制aac(6')-lb的表达。为了开发两种通过不同机制抑制aac(6')-lb表达的反义化合物,我们设计了具体目标1和2: 1.鉴定促进RNA酶H介导的aac(6')-1b mRNA降解的核酸酶抗性寡脱氧核苷酸类似物。我们将设计核酸酶抗性类似物并测试它们介导表型转化为阿米卡星敏感性的能力并确定作用机制。 2.通过寡核糖核苷酸进行RNase P介导的aac(6')-lb mRNA降解的体内研究以及对核酸酶抗性寡核糖核苷酸类似物诱导RNase P裂解的能力的系统分析。我们将设计编码选定寡核糖核苷酸的质粒,并测试它们是否诱导 RNase P 介导的阿米卡星敏感性转化。我们还将对核酸酶抗性寡核糖核苷酸类似物进行系统研究,以确定哪些(如果有的话)不会损害 RNase P 介导的 RNA 切割。 虽然实现具体目标 1 和 2 将是开发反义化合物以保持阿米卡星功效的重要一步,但许多问题仍有待解决。其中两个问题是:a) 确保反义化合物到达细菌细胞细胞质的递送方法非常有限; b) aac(6')-lb基因通常存在于高拷贝数质粒中;因此,大量的基因拷贝可能使得完全关闭表达变得非常困难。具体目标 3 和 4 旨在解决这些问题: 3.开发能够将寡核苷酸递送至细胞胞浆中的脂质体制剂。我们将测试几种阳离子脂质体封装的寡核苷酸类似物制剂到达细胞质的能力。内化过程将通过荧光显微镜来表征。 4.寻找AAC(6')-1b酶的肽抑制剂。酶抑制剂可以通过抑制合成的任何残余AAC(6')-1b蛋白的作用而与反义寡核苷酸具有协同活性。将使用噬菌体展示来搜索肽抑制剂。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARCELO E TOLMASKY其他文献

MARCELO E TOLMASKY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARCELO E TOLMASKY', 18)}}的其他基金

CHERP Cancer Research Education Program
CHERP 癌症研究教育计划
  • 批准号:
    10302809
  • 财政年份:
    2021
  • 资助金额:
    $ 20.91万
  • 项目类别:
CHERP Administrative Core
CHERP 管理核心
  • 批准号:
    10492740
  • 财政年份:
    2021
  • 资助金额:
    $ 20.91万
  • 项目类别:
1/2 CSUF/UCI-CFCCC Cancer Health Disparities Research Program (CHERP)
1/2 CSUF/UCI-CFCCC 癌症健康差异研究计划 (CHERP)
  • 批准号:
    10684039
  • 财政年份:
    2021
  • 资助金额:
    $ 20.91万
  • 项目类别:
1/2 CSUF/UCI-CFCCC Cancer Health Disparities Research Program (CHERP)
1/2 CSUF/UCI-CFCCC 癌症健康差异研究计划 (CHERP)
  • 批准号:
    10492739
  • 财政年份:
    2021
  • 资助金额:
    $ 20.91万
  • 项目类别:
1/2 CSUF/UCI-CFCCC Cancer Health Disparities Research Program (CHERP)
1/2 CSUF/UCI-CFCCC 癌症健康差异研究计划 (CHERP)
  • 批准号:
    10302802
  • 财政年份:
    2021
  • 资助金额:
    $ 20.91万
  • 项目类别:
CHERP Cancer Research Education Program
CHERP 癌症研究教育计划
  • 批准号:
    10492749
  • 财政年份:
    2021
  • 资助金额:
    $ 20.91万
  • 项目类别:
CHERP Cancer Research Education Program
CHERP 癌症研究教育计划
  • 批准号:
    10684045
  • 财政年份:
    2021
  • 资助金额:
    $ 20.91万
  • 项目类别:
CHERP Administrative Core
CHERP 管理核心
  • 批准号:
    10302803
  • 财政年份:
    2021
  • 资助金额:
    $ 20.91万
  • 项目类别:
CHERP Administrative Core
CHERP 管理核心
  • 批准号:
    10684040
  • 财政年份:
    2021
  • 资助金额:
    $ 20.91万
  • 项目类别:
Dealing with antibiotic resistance: antisense technology
应对抗生素耐药性:反义技术
  • 批准号:
    10514492
  • 财政年份:
    2000
  • 资助金额:
    $ 20.91万
  • 项目类别:

相似海外基金

Disrupting Dogma: Investigating LPS Biosynthesis Inhibition as an Alternative Mechanism of Action of Aminoglycoside Antibiotics
颠覆教条:研究 LPS 生物合成抑制作为氨基糖苷类抗生素的替代作用机制
  • 批准号:
    10653587
  • 财政年份:
    2023
  • 资助金额:
    $ 20.91万
  • 项目类别:
Shaping Next Generation Aminoglycoside Antibiotics for Treatment of Multidrug-Resistant Diseases
打造下一代氨基糖苷类抗生素治疗多重耐药性疾病
  • 批准号:
    10585038
  • 财政年份:
    2023
  • 资助金额:
    $ 20.91万
  • 项目类别:
Creation of Next-generation Aminoglycoside Antibiotics Active against Multidrug-resistant Gram-negative Bacteria
开发对多重耐药革兰氏阴性菌具有活性的下一代氨基糖苷类抗生素
  • 批准号:
    20K06982
  • 财政年份:
    2020
  • 资助金额:
    $ 20.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Shaping Next Generation Aminoglycoside Antibiotics for Treatment of Multidrug- Resistant Diseases
打造下一代氨基糖苷类抗生素治疗多重耐药性疾病
  • 批准号:
    9934590
  • 财政年份:
    2019
  • 资助金额:
    $ 20.91万
  • 项目类别:
Combating Antibiotic Resistance to Aminoglycoside Antibiotics through Chemical Synthesis
通过化学合成对抗氨基糖苷类抗生素的耐药性
  • 批准号:
    392481159
  • 财政年份:
    2017
  • 资助金额:
    $ 20.91万
  • 项目类别:
    Research Fellowships
Shaping Next Generation Aminoglycoside Antibiotics for Treatment of Multidrug-Resistant Diseases
打造下一代氨基糖苷类抗生素治疗多重耐药性疾病
  • 批准号:
    9082038
  • 财政年份:
    2016
  • 资助金额:
    $ 20.91万
  • 项目类别:
Functional analysis of radical SAM enzymes involved in the biosynthesis of aminoglycoside antibiotics
氨基糖苷类抗生素生物合成中自由基SAM酶的功能分析
  • 批准号:
    26410174
  • 财政年份:
    2014
  • 资助金额:
    $ 20.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
EAPSI:Synthesis of Aminoglycoside Antibiotics
EAPSI:氨基糖苷类抗生素的合成
  • 批准号:
    1106886
  • 财政年份:
    2011
  • 资助金额:
    $ 20.91万
  • 项目类别:
    Fellowship Award
Preclinical evaluation of aminoglycoside antibiotics-derived amphiphiles (AADAs)
氨基糖苷类抗生素衍生的两亲物 (AADA) 的临床前评估
  • 批准号:
    185482
  • 财政年份:
    2009
  • 资助金额:
    $ 20.91万
  • 项目类别:
    Operating Grants
AMINOGLYCOSIDE ANTIBIOTICS FOR CYSTIC FIBROSIS
治疗囊性纤维化的氨基糖苷类抗生素
  • 批准号:
    6565399
  • 财政年份:
    2001
  • 资助金额:
    $ 20.91万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了